H. Kotani

发表

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2010, Cell cycle.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2011, Investigational New Drugs.

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

P. Majumder, Hiroshi Sootome, H. Hirai, 2010, Molecular Cancer Therapeutics.

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples

T. Machida, H. Kotani, S. Mizuarai, 2011, Molecular Cancer.

Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation

H. Kotani, S. Mizuarai, H. Itadani, 2008, Current genomics.

Expression levels of p 18 INK 4 C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

H. Hirai, Makiko Kobayashi, T. Arai, 2010, Cancer biology & therapy.

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

H. Hirai, T. Arai, H. Kotani, 2009, Molecular Cancer.

Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells.

H. Kotani, Tsutomu Kobayashi, H. Itadani, 2003, Kidney international.

Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders.

H. Kotani, Kazuhiko Takahashi, S. Tokita, 2006, Journal of pharmacological sciences.

Expression levels of p18 INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

T. Shimomura, Koji Ichikawa, Shinichi Hasako, 2010, Molecular Cancer Therapeutics.

Generation and Characterization of Highly Constitutive Active Histamine H3 Receptors

H. Kotani, Kazuhiko Takahashi, S. Tokita, 2003, Journal of Pharmacology and Experimental Therapeutics.

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.

T. Machida, K. Haze, Y. Nakatsuru, 2009, Bioorganic & medicinal chemistry letters.

Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.

H. Kotani, Kazuhiko Takahashi, Hiroaki Suwa, 2002, The Journal of clinical investigation.

Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers.

H. Hirai, T. Eguchi, H. Kotani, 2009, Genomics.

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Tsuyoshi Arai, Hiroshi Hirai, Takashi Yoshizumi, 2009, Molecular Cancer Therapeutics.

Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.

M. Taketo, T. Minamoto, H. Kotani, 2009, Gastroenterology.

[Novel anti-cancer compounds targeting the cell cycle].

H. Hirai, T. Shimomura, H. Kotani, 2009, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.

H. Kotani, S. Nishimura, H. Komatani, 2001, Cancer research.

Identification of Dicarboxylate Carrier Slc25a10 as Malate Transporter in de Novo Fatty Acid Synthesis*

H. Kotani, S. Mizuarai, Hiromitsu Araki, 2005, Journal of Biological Chemistry.

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

H. Kotani, S. Mizuarai, N. Aozasa, 2004, International journal of cancer.

Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography.

R. Yoshimoto, H. Kotani, A. Kanatani, 2004, Analytical biochemistry.

Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer

H. Kotani, M. Oshima, H. Itadani, 2009, BMC Genomics.

Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus

D. Macneil, R. Yoshimoto, H. Kotani, 2006, Proceedings of the National Academy of Sciences.

Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice*

H. Kotani, S. Mizuarai, H. Itadani, 2003, Journal of Biological Chemistry.

Crystal structures of the N‐terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors

S. Munshi, H. Kotani, M. Ikuta, 2007, Protein science : a publication of the Protein Society.

RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene

T. Eguchi, H. Kotani, T. Takaki, 2007, Oncogene.

Advances in isolation and characterization of homogeneous cell populations using laser microdissection.

H. Kotani, S. Mizuarai, K. Takahashi, 2005, Histology and histopathology.

High-throughput assay for long chain fatty acyl-CoA elongase using homogeneous scintillation proximity format.

H. Kotani, Tsutomu Kobayashi, S. Tokita, 2009, Assay and drug development technologies.

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.

H. Kotani, S. Mizuarai, Kazunori Yamanaka, 2006, Cancer research.

Role of the Toll-like Receptor 4/NF-&kgr;B Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages

S. Yamaoka, Y. Kamei, H. Kotani, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009, Molecular Cancer Therapeutics.

Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.

M. Taketo, H. Kotani, M. Oshima, 2009, Cancer research.

Impaired drinking response in histamine H3 receptor knockout mice following dehydration or angiotensin-II challenge

R. Yoshimoto, H. Kotani, A. Kanatani, 2006, Pharmacology Biochemistry and Behavior.

Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding.

Takashi Yoshizumi, K. Fukasawa, H. Kotani, 2010, Acta crystallographica. Section D, Biological crystallography.

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements

H. Kotani, S. Mizuarai, Shinji Mizuarai, 2010, Human Genetics.

Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines

H. Kotani, S. Mizuarai, A. Kawagishi, 2009, Molecular Cancer.

Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice

H. Kotani, Jian-Sheng Lin, H. Akaoka, 2013, Neuropsychopharmacology.

Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus

D. Macneil, R. Yoshimoto, H. Kotani, 2006, Proceedings of the National Academy of Sciences.